



IFW

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0 031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(To be used for all correspondence  
after initial filing)

Application Number	10/781,340
Filing Date	February 17, 2004
First Named Inventor	Neil S. Cutshall
Group Art Unit	
Examiner Name	
Attorney Docket No.	60117-106

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO/SB/08 <input type="checkbox"/> Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group ( <i>Appeal Notice, Brief, Reply Brief</i> ) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input checked="" type="checkbox"/> Additional Enclosure(s) ( <i>please identify below</i> ): <u>Request to Amend Attorney Docket Number</u> _____ _____
---	--	--

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Jane E. R. Potter	27476
Signature		
Date	May 21, 2004	

## CERTIFICATE OF FACSIMILE TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date specified below.

Typed or printed name	Jessica Gaunt	
Signature		Date: May 21, 2004

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 21, 2004

Date

*Jessica Gaunt*

Jessica Gaunt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Neil S. Cutshall et al.  
Application No. : 10/781,340  
Filed : February 17, 2004  
For : PHARMACEUTICAL USES AND SYNTHESIS OF  
NICOTINANILIDE-N-OXIDES

Docket No. : 60117-106

Date : May 21, 2004

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO/SB/08. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 10/015,861, filed December 12, 2001. The references listed on the attached form PTO/SB/08 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office

in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

No fee is due at this time in accordance with 37 C.F.R. § 1.97(b).

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,  
Neil S. Cutshall et al.  
DAVIS WRIGHT TREMAINE LLP


By   
Jane E. R. Potter  
Registration No. 33,332

2600 Century Square  
1501 Fourth Avenue  
Seattle, WA 98101-1688  
Phone: (206) 628-7650  
Facsimile: (206) 628-7699



PATENT

Whereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

May 21, 2004		
Date		Jessica Gaunt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Neil S. Cutshall et al.  
Application No. : 10/781,340  
Filed : February 17, 2004  
For : PHARMACEUTICAL USES AND SYNTHESIS OF  
NICOTINANILIDE-N-OXIDES

Docket No. : 60117-106  
Date : May 21, 2004


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST TO AMEND ATTORNEY DOCKET NUMBER**

Sir:

Applicants hereby request the docket number for Application No. 10/781,340 be amended to read 60117-106.

Respectfully submitted,  
Neil S. Cutshall et al.  
DAVIS WRIGHT TREMAINE LLP

By   
Jane E. R. Potter  
Registration No. 33,332

2600 Century Square  
1501 Fourth Avenue  
Seattle, WA 98101-1688  
Phone: (206) 628-7650  
Facsimile: (206) 628-7699



PTO/SB/08A (05-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/781,340
				Filing Date	February 17, 2004
				First Named Inventor	Neil S. Cutshall
				Art Unit	
Sheet	1	of	6	Examiner Name	
				Attorney Docket Number	60117-106

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-6,333,341	12-25-2001		
		US-6,022,884	02-08-2000		
		US-5,472,687	02-05-1995		
		US-4,990,518	02-05-1991		
		US-4,978,385	12-18-1990		
		US-4,055,427	10-25-1977		
		US-3,950,160	04-13-1976		
		US-3,766,195	10-16-1973		
		US-3,637,716	01-25-1972		
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO-02/22599	03-21-2002			
		WO-01/55115	08-02-2001			
		WO-01/14340	03-01-2001			
		WO-99/62885	12-09-1999			
		WO-99/07380	02-18-1999			
		WO-98/07692	02-26-1998			
		DT-2538950 A	03-03-1977			
		GB-1134651	11-27-1968			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450..

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/781,340
				<b>Filing Date</b>	February 17, 2004
				<b>First Named Inventor</b>	Neil S. Cutshall
				<b>Art Unit</b>	
				<b>Examiner Name</b>	
Sheet	2	of	6	<b>Attorney Docket Number</b>	60117-106
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
		CO ET AL., <i>Preparation and Reactions of 2,3,4,6-Tetrafluoropyridine and its Derivatives</i> , JOURNAL OF FLUORINE CHEMISTRY, 101(1):45-60, 2000.			
		CUMMINGS ET AL., <i>Expression and Function of the Chemokine Receptors CXCR1 and CXCR2 in Sepsis</i> , J. IMMUNOL., 162(4):2341-6, 1999.			
		MATSUKAWA ET AL., <i>Involvement of Growth-Related Protein in Lipopolysaccharide-Induced Rabbit Arthritis: Cooperation Between Growth-Related Protein and IL-8, and Interrelated Regulation Among TNF<math>\alpha</math>, IL-1, IL-1 Receptor Antagonist, IL-8, and Growth-Related Protein</i> , LABORATORY INVESTIGATION, 79(5):591-600, 1999.			
		XIA ET AL., <i>Chemokines/chemokine Receptors in the Central Nervous System and Alzheimer's Disease</i> , J. NEUROVIROLOGY, 5(1):32-41, 1999.			
		BOISVERT ET AL., <i>A Leukocyte Homologue of the IL-8 Receptor CXCR-2 Mediates the Accumulation of Macrophages in atherosclerotic Lesions of LDL Receptor-Deficient Mice</i> , J. CLIN. INVEST., 101(2):353-363, 1998.			
		BUKHTIAROVA ET AL., <i>Possibilities for Search for New Analgesics in the Series of Arylamides O Isonicotinic and Nicotinic Acids</i> , CHEMICAL ABSTRACTS SERVICES, STN DATABASE ACCESSION NO. 131:237346, 1998.			
		COLLIE ET AL., <i>Production of Some Nitro- and Amido-Oxylutidines, Part I</i> , JOURNAL OF THE CHEMICAL SOCIETY, 73:229-235, 1998.			
		TERKELTAUB ET AL., <i>Chemokines and Atherosclerosis</i> , CURR. OPIN. LIPIDOL., 9(5):397-405, 1998.			
		TERKELTAUB ET AL., <i>The Murine Homolog of the Interleukin-8 Receptor CXCR-2 is Essential for the Occurrence of Neutrophilic Inflammation in the Air Pouch Model of Acute Urate Crystal-Induced Gouty Synovitis</i> , ARTHRITIS. RHEUM., 41(5):900-909, 1998.			
		WANG ET AL., <i>Chemokines and Their Role in Tumor Growth and Metastasis</i> , J. IMMUNOL. METHODS, 220(1-2):1-17, 1998.			
		WHITE ET AL., <i>Identification of Potent, Selective Non-Peptide CXCR2 Antagonist that Inhibits Interleukin-8-Induced Neutrophil Migration</i> , J. BIOL. CHEM., 273(17):10095-10098, 1998.			
Examiner Signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/781,340
				<b>Filing Date</b>	February 17, 2004
				<b>First Named Inventor</b>	Neil S. Cutshall
				<b>Art Unit</b>	
				<b>Examiner Name</b>	
<b>Sheet</b>	3	<b>of</b>	6	<b>Attorney Docket Number</b>	60117-106
<b>NON PATENT LITERATURE DOCUMENTS</b>					
<b>Examiner Initials*</b>	<b>Cite No. <sup>1</sup></b>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			<b>T<sup>2</sup></b>
		BUKHTIAROVA ET AL., <i>Structure and Anti-Inflammatory</i> , ENGLISH ABSTRACT-CAPLUS-DN-128:289722, 31(11):30-32, 1997.			
		HORUK ET AL., <i>Expression of Chemokine Receptors by Subsets of Neurons in the Central Nervous System</i> , J. IMMUNOL., 158(6):2882-2890, 1997.			
		JONES ET AL., <i>Chemokine Antagonists that Discriminate Between Interleukin-8 Receptors. Selective Blockers of CXCR2</i> , J. BIOL. CHEM., 272(26):16166-16169, 1997.			
		SAMSON ET AL., <i>The Second Extracellular Loop of CCR5 is the Major Determinant of Ligand Specificity</i> , J. BIOL. CHEM., 272(40):24934-24941, 1997.			
		XIA ET AL., <i>Interleukin-8 Receptor B Immunoreactivity in Brain and Neuritic Plaques of Alzheimer's Disease</i> , AM. J. PATHOL., 150(4):1267-1274, 1997.			
		BABI ET AL., <i>The Interleukin-8 Receptor B and CXC Chemokines can Mediate Transendothelial Migration of Human Skin Homing T Cells</i> , EUR. J. IMMUNOL., 26(9):2056-2061, 1996.			
		GILLITZER ET AL., <i>Differential Expression of GRO-Alpha and IL-8 mRNA in Psoriasis: a Model for Neutrophil Migration and Accumulation in Vivo</i> , J. INVEST. DERMATOL., 107(5):778-782, 1996.			
		GOODMAN ET AL., <i>Inflammatory Cytokines in Patients with Persistence of the Acute Respiratory Distress Syndrome</i> , AM. J. RESPIR. CRIT. CARE MED., 154(3 PT 1):602-611, 1996.			
		QUAN ET AL., <i>Antibodies Against the N-Terminus of IL-8 Receptor A Inhibit Neutrophil Chemotaxis</i> , BIOCHEMICAL BIOPHYSICAL RESEARCH COMMUNICATIONS, 219(2):405-411, 1996.			
		CHUNTHARAPAI ET AL., <i>Regulation of the Expression of IL-8 Receptor A/B by IL-8: Possible Functions of Each Receptor</i> , J. IMMUNOL., 155(5):2587-2594, 1995			
		HAMMOND ET AL., <i>IL-8 Induces Neutrophil Chemotaxis Predominantly Via Type I IL-8 Receptors</i> , J. IMMUNOL., 155(3):1428-1433, 1995.			
<b>Examiner Signature</b>				<b>Date</b>	
				<b>Considered</b>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/781,340
				<b>Filing Date</b>	February 17, 2004
				<b>First Named Inventor</b>	Neil S. Cutshall
				<b>Art Unit</b>	
				<b>Examiner Name</b>	
<b>Sheet</b>	4	<b>of</b>	6	<b>Attorney Docket Number</b>	60117-106
<b>NON PATENT LITERATURE DOCUMENTS</b>					
<b>Examiner Initials*</b>	<b>Cite No. <sup>1</sup></b>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			<b>T<sup>2</sup></b>
		VILLARD ET AL., <i>GRO Alpha and Interleukin-8 in Pneumocystis Carinii or Bacterial Pneumonia and Adult Respiratory Distress Syndrome</i> , AM. J. RESPIR. CRIT. CARE MED., 152(5 PT 1):1549-54, 1995.			
		XU ET AL., <i>Modulation of IL-8 Receptor Expression on Purified Human T Lymphocytes is Associated with Changed Chemotactic Responses to IL-8</i> , J. LEUKOC. BIOL., 57(2):335-342, 1995.			
		CHUNTHARAPAI ET AL., <i>Monoclonal Antibodies Detect Different Distribution Patterns of IL-8 Receptor A and IL-8 Receptor B on Human Peripheral Blood Leukocytes</i> , J. IMMUNOL., 153(12):5682-5688, 1994.			
		DONNELLY ET AL., <i>Mediators, Mechanisms and Mortality in Major Trauma</i> , RESUSCITATION, 28(2):87-92, 1994.			
		SCHWARTZ ET AL., <i>Role of the GRO Family of Chemokines in Monocyte Adhesion to MM-LDL-Stimulated Endothelium</i> , J. CLIN. INVEST., 94(5):1968-1973, 1994.			
		SIMPSON ET AL., <i>Pulmonar Injury Following Sepsis</i> , PROG. CLIN. BIOL. RES., 388:265-275, 1994.			
		DONNELLY ET AL., <i>Trauma, Inflammatory Cells and ARDS</i> , ARCH. EMERG. MED., 10(2):108-11, 1993.			
		KOJIMA ET AL., <i>GRO-<math>\alpha</math> mRNA is Selectively Overexpressed in Psoriatic Epidermis and is Reduced by Cyclosporin A in Vivo, but Not in Cultured Keratinocytes</i> , J. INVEST. DERMATOLOGY, 101(6):767-772, 1993.			
		BOUZARD ET AL., <i>Fluoronaphthyridines as Antibacterial Agents. 4. Synthesis and Structure-Activity Relationships of 5-Substituted-6-Fluoro-7-(Cycloalkylamino)-1,4-Dihydro-4-Oxo-1,8-Naphthyridine-3-Carboxylic Acids</i> , J. MED. CHEM, 35:518-525, 1992.			
		IZZO ET AL., <i>Interleukin-8 and Neutrophil Markers in Colonic Mucosa from Patients with Ulcerative Colitis</i> , AM. J. GASTROENTEROLOGY, 87(10):1447-1452, 1992.			
		MAHIDA ET AL., <i>Enhanced Synthesis of Neutrophil-Activating Peptide1/Interleukin-8 in Active Ulcerative Colitis</i> , CLINICAL SCIENCE (LONDON), 82(3):273-275, 1992.			
<b>Examiner Signature</b>				<b>Date Considered</b>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/781,340
				Filing Date	February 17, 2004
				First Named Inventor	Neil S. Cutshall
				Art Unit	
				Examiner Name	
Sheet	5	of	6	Attorney Docket Number	60117-106
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
		ENDO ET AL., <i>Elevation of Interleukin-8 (IL-8) Levels in Joint Fluids of Patients with Rheumatoid Arthritis and the Induction by IL-8 of Leukocyte Infiltration and Synovitis in Rabbit Joints</i> , LYMPHOKINE AND CYTOKINE RESEARCH, 10(4):245-252, 1991.			
		HOLMES ET AL., <i>Structure and Functional Expression of a Human Interleukin-8 Receptor</i> , SCIENCE, 253(5025):1278-1280, 1991.			
		MURPHY ET AL., <i>Cloning of Complementary DNA Encoding a Functional Human Interleukin-8 Receptor</i> , SCIENCE, 253(5025):1278-1280, 1991.			
		REPINE ET AL., <i>Neutropils and Adult Respiratory Distress Syndrome: Two Interlocking Perspectives in 1991</i> , AM. REV. RESPIR. DIS., 144:251-252, 1991.			
		FUHLENDORFF ET AL., [Leu <sup>31</sup> , Pro <sup>34</sup> ]Neuropeptide Y: a Specific Y <sub>1</sub> Receptor Agonist, PNAS USA, 87(1):182-186, 1990.			
		GOLDMAN ET AL., <i>Tumor Necrosis Factor-α Mediates Acid Aspiration-Induced Systemic Organ Injury</i> , ANN. SURG., 212(4):513-520, 1990.			
		GROB ET AL., <i>Characterization of a Receptor for Human Monocyte-Derived Neutrophil Chemotactic Factor/Interleukin-8</i> , J. BIOL. CHEM., 265(14):8311-8316, 1990.			
		BESEMER ET AL., <i>Specific Binding, Internalization, and Degradation of Human Neutrophil Activating Factor by Human Polymorphonuclear Leukocytes</i> , J. BIOL. CHEM., 264(29):17409-17415, 1989.			
		SAMATA ET AL., <i>Identification and Characterization of Specific Receptors for Monocyte-Derived Neutrophil Chemotactic Factor (MDNCF) on Human Neutrophils</i> , J. EXP. MED., 169(3):1185-1189, 1989.			
		SHEIKH ET AL., <i>Binding of Monoiodinated Neuropeptide Y to Hippocampal Membranes and Human Neuroblastoma Cell Lines</i> , J. BIOL. CHEM., 264(12):6648-6654, 1989.			
		LINAS ET AL., <i>Neutrophils accentuate Ischemia-Reperfusion Injury in Isolated Perfused Rat Kidneys</i> , A. J. PHYSIOLOGY, 255(4 PT 2):F728-F735, 1988.			
Examiner Signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/781,340
				<b>Filing Date</b>	February 17, 2004
				<b>First Named Inventor</b>	Neil S. Cutshall
				<b>Art Unit</b>	
				<b>Examiner Name</b>	
Sheet	6	of	6	<b>Attorney Docket Number</b>	60117-106
<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
		THERMOS ET AL., <i>Somatostatin Receptor Subtypes in the Clonal Anterior Pituitary Cell Lines at AtT-20 and GH3</i> , MOL. PHARMACOL., 33(4):370-377, 1988.			
		SRIKANT ET AL., <i>Relationship Between Receptor Binding and Biopotency of Somatostatin-14 and Somatostatin-28 in Mouse Pituitary Tumor Cells</i> , ENDOCRINOLOGY, 117(1):271-278, 1985.			
		KLEBANOV ET AL., <i>Antiinflammatory Activity of Some New Pyridine Carboxylic Acid Derivatives</i> , CHEMICAL ABSTRACTS SERVICES, STN DATABASE ACCESSION NO. 88:15765, 1977.			
		LAMM, <i>2,6-Dichloronicotinic Acids</i> , CHEMICAL ABSTRACTS, ABSTRACT NO. 1977:189730, SEE ALSO DT2538950, 1977.			
		SCHNEKENBURGER ET AL., ENGLISH ABSTRACT-CAPLUS-DN-81:169412, 1974.			
		MIREK ET AL., <i>Intramolecular Hydrogen Bond</i> , ENGLISH ABSTRACT-CAPLUS-DN-75:75600, 45(2):205-9, 1971.			
		CHAMBON ET AL., <i>Toxicity and Pharmacodynamic Properties of N,N-Diethylnicotinamide N-Oxide (Coramine N-Oxide)</i> , CHEMICAL ABSTRACTS SERVICES, STN DATABASE ACCESSION NO. 71:89704, 1969.			
		CHAMBERS ET AL., <i>Polyfluoronaphthyridines Compounds. Part V. Catalytic Reduction of Perfluoro- and Chlorofluoro-Pyridines and the Preparation of Polyfluoropyridinecarboxylic Acids</i> , JOURNAL OF THE CHEMICAL SOCIETY, 5045-5048, 1965.			
		STREIGHTOFF ET AL., <i>Inhibition of Bacteria by 5-Fluoronicotinic Acid and Other Analogs of Nicotinic Acid</i> , CHEMICAL ABSTRACTS, 58(5):ABSTRACT NO. 4836A, 1963.			
		WEILAND ET AL., <i>Syntheses of 4-Substituted Nicotinamides Via the N-Oxides</i> , CHEMISCHE BERICHTE, 96:266-274, 1963.			
		WEILAND ET AL., <i>Syntheses of 4-Substituted Nicotinamides Via the N-Oxides</i> , CHEMICAL ABSTRACTS SERVICES, STN DATABASE ACCESSION NO. 1963:66395, 1963.			
		DORNOW ET AL., <i>Synthese Von 2-Oxy-Imidazolo-(5',4':2,3)-Pyridinen. Synthesen Stickstoffhaltiger Heterocyclen, XII. Mitteilung.</i> , ARCHIV. DER. PHARMAZIE., 290:20-31, 1957.			
		DORNOW ET AL., <i>Synthesis of N-Containing Heterocycles. XII. Synthesis of 2-Hydroxy-1-Imidazo[b]pyridines</i> , CHEMICAL ABSTRACTS, ABSTRACT NO. 1957:56771, 1957.			
Examiner Signature				Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.